Abstract: Described herein is a multi-dimensional kineticardiography device (300) which comprises a sensor (320) having three accelerometer/gyroscope modules (320X, 320Y, 320Z) mounted in a support which positions it at the centre of mass of a subject whose cardiac function is to be measured. The sensor (320) outputs six degrees of freedom data as linear acceleration along and rotational or angular velocity about x-, y- and z-axes. The sensor (320) is connected to a processor (335) for transmitting the kineticardiography data obtained from the sensor (320) and the electrocardiography data to a mobile computing platform (330), via Bluetooth (350), for further processing and display. An electrocardiography data chip (370) is also present for digitising the electrocardiography data for further processing.

Abstract: Some embodiments relate to a method for producing a product of interest with a microbial host using an auto-replicative extra-chromosomal nucleic acid molecule comprising a first nucleic acid sequence whose genetic activity confers an advantage to the host, optionally wherein the genetic activity of said first nucleic acid molecule is controlled.

Abstract: A device for generating bubbles or droplets may include a cavity comprising a first pressurized phase, at least one input capillary of a second phase, and an output capillary coaxially aligned with the at least one input capillary. The opening of the tip of the at least one input capillary has an internal diameter of less than half the internal diameter of the output capillary. The cross section of the cavity may be selected so that, in use, the average speed field in the cavity is quasi-static.

Abstract: Novel therapeutic agents, particularly those capable of activating (GPR)124/RECK/Frizzled/lipoprotein receptor-related protein (LRP)-mediated Wnt signaling, while not activating Frizzled/LRP-mediated Wnt signaling in the absence of RECK and/or GPR124. The agents are particularly useful for the prevention or treatment of neurovascular disorders or central nervous system (CNS) disorders including neurovascular dysfunction.

Abstract: A method for assessing a state of health of a battery having a plurality of heterogeneous cells includes subjecting the cells of the battery to a plurality of diagnostic current pulse cycles; identifying extreme cells based upon the cycles; estimating model parameters of the extreme cells; and estimating upper and lower bounds for the estimated model parameters. Estimating model parameters includes performing a recursive least squares analysis on the extreme cells. Estimating the upper and lower bounds for the estimated model parameters includes performing a sparse Gaussian process regression using the estimated model parameters.

Abstract: A method of predicting state of power (SOP) for a battery includes estimating first state parameter bounds of the battery using an internal observer process; obtaining a current value based upon the first state parameter bounds, system constraint variables, a scaling factor and a reference current using a modified reference governor process; performing adaptive parameter bounding to obtain second state parameter bounds using the current value; determining a constraint variable based upon the second state parameter bounds and whether the constraint variable is within the system constraint variables the using an interval prediction process; and generating a modified scaling factor based upon whether the constraint variable is within the system constraint variables. Using the modified scaling factor, the obtaining, performing, determining and modifying are repeated to generate a final current value. The SOP is estimated based upon the final current value.

Abstract: The present disclosure relates generally to regulatory T cells (Tregs) engineered to express a dipeptidyl aminopeptidase-like protein 6 (DPP6)-reactive chimeric antigen receptor (CAR). The engineered Tregs are suitable for use in immunotherapy regimens for autoimmune, inflammatory and degenerative diseases. In particular, the anti-DPP6 CAR expressing Tregs are suitable for treating or preventing autoimmune diseases of the pancreas or central nervous system.

Abstract: The present disclosure relates generally to stents, systems, and methods for gastrointestinal treatment. In some embodiments, a stent may include a tubular scaffold having a first end opposite a second end, wherein a lumen extends between the first and second ends. The tubular scaffold may include a flared section and a medial section extending from the flared section, wherein a first diameter of the flared section is greater than a second diameter of the medial section. The stent may further include a liner extending partially along a surface of the tubular scaffold, wherein the liner is spaced from an anchoring region of the flared section to promote tissue ingrowth with the flared section.

Abstract: Described herein is a yeast strain wherein activity of one or more membrane transporters of the DHA1 family is reduced relative to a wild type strain or to a parental strain from which it is derived.

Abstract: The present disclosure relates generally to stents, systems, and methods for gastrointestinal treatment. In some embodiments, a stent may include a tubular scaffold having a first end opposite a second end, wherein a lumen extends between the first and second ends. The tubular scaffold may include a flared section and a medial section extending from the flared section, wherein a first diameter of the flared section is greater than a second diameter of the medial section. The stent may further include a liner extending partially along a surface of the tubular scaffold, wherein the liner is spaced from an anchoring region of the flared section to promote tissue ingrowth with the flared section.

Abstract: The present invention concerns screening methods to identify compounds that regulate activity of RSH enzymes such as Rel, and specifically Rel synthetase and/or Rel hydrolase activity. Also intended are compounds that interact and regulate Rel synthetase and/or hydrolase activity. These compounds are valuable to target persister cells not affected by traditional antibiotics.

Abstract: This invention concerns a versatile and simple one-pot method to prepare nanomaterials, and in particular nanoparticles, grafted with an ultra-thin layer of calixarenes by placing at 5 least one oxidized metal with at least one calix[n]arene diazonium salt in the presence of a reducing agent in a solvent, and heating the traction mixture to obtain a metal-based nanomaterial coated with calix[n]arenes. The invention further concerns the coupling of organic molecules or biomolecules to the calixarene-grafted nanomaterials in order to further functionalize the surface of the particles. The metal-based nanomaterial coated with 10 calix[n]arenes can for example be used in immunoassays.

Abstract: A device for shearing tissue in a human or animal body may include a first member made of a first material and a second member made of a second material. A thread is connected to the first member and to the second member, and the first and second materials show magnetic attraction between one another. A means is provided for pulling the thread between the first and second members.

Abstract: The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration).

Abstract: A kit for an inhaled chemotherapy includes a series of single hermetically packaged therapeutic doses of a dry powder for inhalation. The dry powder includes at least one anti-neoplastic agent chosen from the group that includes platinum drugs with a lipid matrix and a PEGylated excipient and a series of disposable dry powder inhaler devices. The use and a method of treatment of cancer lungs with said kit is also described.

Abstract: A dry powder inhalation formulation includes at least one active pharmaceutical ingredient (API) and a lipid matrix having at least one triglyceride chosen in the group consisting of monohydroxystearin, dihydroxystearin, trihydroxystearin and their mixture and its manufacturing method.

Abstract: An interval observer based on an equivalent circuit-thermal model for lithium-ion batteries is presented. State of charge-temperature-dependent parameters are considered as unknown but bounded uncertainties in a single cell model. A parallel and a series arrangement of five cells are used for observer design, where cell heterogeneity is accounted for through the uncertainty bounding functions.

Abstract: An interval observer based on an equivalent circuit-thermal model for lithium-ion batteries is presented. State of charge-temperature-dependent parameters are considered as unknown but bounded uncertainties in a single cell model. A parallel and a series arrangement of five cells are used for observer design, where cell heterogeneity is accounted for through the uncertainty bounding functions.

Abstract: A method for manufacturing an ?+? Ti-6Al-4V alloy includes providing a near-net shape part made of an ?+? Ti-6Al-4V alloy, The part is heat treated in the ?+? field between 875 and 920° C. The heat treated part is water quenched to transform the ? phase into ?? martensite. There is no further heat treatment after the quenching step.

Abstract: This invention relates to the direct grafting of a calixarene mostly onto the surface of a material, as well as to a grafting process, and certain calixarene intermediates useful for carrying the grafting process.